Alcon Inc. (ETR:2U3)
Germany
· Delayed Price · Currency is EUR | Market Cap | 36.61B |
| Revenue (ttm) | 9.18B |
| Net Income (ttm) | 1.04B |
| Shares Out | n/a |
| EPS (ttm) | 2.08 |
| PE Ratio | 35.33 |
| Forward PE | 26.02 |
| Dividend | 0.30 (0.40%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | n/a |
| Average Volume | 0 |
| Open | 74.50 |
| Previous Close | 74.10 |
| Day's Range | 74.38 - 74.50 |
| 52-Week Range | 73.36 - 85.94 |
| Beta | n/a |
| RSI | 48.89 |
| Earnings Date | Aug 20, 2025 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial numbers in USD Financial StatementsNews
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon PanOptix Pro intraocular lens (IOL) for cataract patients in C...
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intrao...
Alcon's Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold'
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (N...
LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSA...
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
The U.S. Food and Drug Administration (FDA) on Wednesday approved Alcon Plc’s (NYSE: ALC) Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for signs and symptoms of Dry Ey...
US FDA approves Alcon's new dry-eye drug
Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).
Alcon up 4% as FDA approves Tryptyr drops for dry eye
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250526316115/en/ TRYPTYR (acoltremon ophthalmic solution) 0.003% logo Alco...
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease.
Turkey Contact Lens Market - Competition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more
The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand f...
American Eagle Slumps After Weak Q1 Preview, Analyst Cuts Forecasts On Demand Concerns
JP Morgan analyst Matthew R. Boss reiterated the Neutral rating on American Eagle Outfitters, Inc. (NYSE: AEO), lowering the price forecast from $10 to $9. American Eagle shares fell nearly 15% in af...
Alcon updates 2025 sales growth target to 6%-7% driven by new product launches and tariff mitigation
Alcon Inc. (ALC) Q1 2025 Earnings Call Transcript
Alcon Inc. (NYSE:ALC) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ETCompany ParticipantsDan Cravens - Vice President, Investor RelationsDavid...
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of Alcon Inc (NYSE: ALC) fell sharply in today's pre-market trading as the company posted dow...
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.
Alcon Inc. 2025 Q1 - Results - Earnings Call Presentation
Swiss eye care firm Alcon drops after earnings miss, flags tariff impact
Alcon (NYSE:ALC) shares fell 9% in premarket trading on Wednesday, after the Swiss-American pharmaceutical and medical device company missed estimates for quarterly earnings.
Alcon Non-GAAP EPS of $0.73 misses by $0.03, revenue of $2.5B misses by $20M
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ending March 31, 2025. For the first quarter of 2025, sales were $2.5 billion, flat on a report...
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
GENEVA--(BUSINESS WIRE)--Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS.
Alcon Earnings Preview
Alcon (NYSE: ALC) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement. Analysts estimate that Alcon will report an e...
Alcon Announces Results of 2025 Annual General Meeting
Regulatory News: Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2025 Annual Gene...
Alcon Announces Results of 2025 Annual General Meeting
GENEVA--(BUSINESS WIRE)--Alcon Announces Results of 2025 Annual General Meeting.
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
GENEVA--(BUSINESS WIRE)--Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS.